The world is experiencing rapid transformations
in the development of new approaches to improving human health and the health
of communities, healthcare provision, governance over the use and pricing of
drugs and medicines, and medical innovations in biotechnology (genomics and
stem cell-based therapies). For example, open innovation systems and sharing in
the commons have introduced healing medicines and medical innovations (e.g. the
Human Genome Project). At the same time, there is growing inequality in who
gets access to medical care and medicines, and at what price.
Meanwhile, market competition has in part led to
the opioid crisis of addiction in the United States, human subjects abuses in
developing countries in the race to develop new drugs, and a decline in the
discovery of radical new innovations in medicines for poor populations.This
mini-conference aims to convene
a group of related panels around issues in global health and medicines, to
facilitate useful critical discussion and reflection on participants’
works-in-progress. Driving questions include:
-What theoretical advances are being made in
understanding causal mechanisms in improving, or undermining human health and
community health, for example, through state policy and firm and organizational
strategy? What new frameworks and methods are being developed
to identify key actors and explain actions (e.g. improving, or undermining
health, broadly defined)?
is the evolving role of the state, healthcare systems and professions, and
other actors (multilateral bodies, firms, non-profit organizations) in medical
and medicine provision and innovation? Are we seeing a shift from traditional
dominant blocks (North America and Europe) to new actors (Asia and the Global
South)? Likewise, how have states and healthcare organizations been effective
(or ineffective, indifferent) in the valuation and pricing of medicines (fair,
equitable, and affordable access to life saving medicines)?
-What should be the responsibility, if any, of
the global intellectual property rights regime as arbitrated by such
powerful organizations as the World Trade Organization and global corporations
in monitoring access and benefit sharing of profits resulting from research and
development into new drugs and medicines?
-What are the roles for regulation and
institutionalization of markets for such boundary-products between medicine and
health food as probiotics, herbals, so-called nutraceuticals, and other dietary
supplements – in ensuring the health and safety of consumers and patients?
what way is current research and policy aiming for “inclusive” innovation (e.g.
in healthcare provision, new drug discovery) focused on distributive aspects
versus stakeholder inclusion, or both (e.g. under the United Nations
Sustainable Development Goals (SDGs))? What is the relative role for
(social) entrepreneurs, large firms, and other actors?
mini-conference encourages submissions of papers exploring emerging frameworks
and theories, as well as empirically rich original data from the developed and
developing world and at various levels of analysis (e.g. local community, firm,
state, multilateral institution). Scholars at all levels are welcome. In the spirit of innovation and
creativity, the panels will have an interactive workshop format around
discussant feedback and moderated audience participation.For more information, contact the
co-organizers at medhealthSASE2020@gmail.com or
see the SASE 2020 website here: https://sase.org/event/2020-amsterdam/. Instructions for submissions here: https://sase.org/events/conference-submission-and-award-guidelines/
order to submit an abstract create a log in profile in order to access the
submission portal. Scroll down to “free account”. No need to join SASE in order
to submit a proposal: https://sase.org/join-sase/